Sort by
Refine Your Search
-
believe everyone has the right to good health. As the oldest and largest health management program in Australia, our School is a pioneer in public health, global health, infectious diseases intelligence
-
ANSTO (Australia), Imperial College London (UK), and Tokamak Energy (UK), is launching a groundbreaking research program focused on developing new materials for compact tokamak reactors. We are recruiting
-
) Sydney, in partnership with ANSTO (Australia), Imperial College London (UK), and Tokamak Energy (UK), is launching a groundbreaking research program focused on developing new materials for compact tokamak
-
shielding, radiation damage, particle transport. Computational skills allowing to compose or modify comprehensive simulation open-source codes. Experience in data analysis and simulations of complex and
-
to opportunity. Full details can be found in the position description. How to apply: Please click on Apply now to make an application. Applications should not be sent to the contact listed below. Please provide a
-
on Apply now to apply online. Applications should not be sent to the contact listed below. Please provide a resume and a separate document addressing the skills and experience listed in the Position
-
Employee Assistance Program For more information check out our benefits page! Your New Team – “ARC Centre of Excellence for Transformative Meta-Optical System“ https://www.tmos.org.au/work-with-tmos/ TMOS
-
contribution of 17% superannuation applies. 24 Months Fixed term Part time position until Oct 2027. This postdoctoral position in computational cognitive science and data science offers an exciting opportunity
-
to the online application form. Please ensure you submit a cover letter, a resume, and a document of your responses to all of the selection criteria for the position as listed above and contained in the selection
-
Doctoral Scientist position. This position will report to Professor Jose Polo, Lead of the Cancer Epigenetics Program at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Inaugural